X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Lead Product(s): Clonidine
Therapeutic Area: Psychiatry/Psychology Product Name: Onyda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2024
Details:
Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their treatment journey.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Dyanavel XR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Perigon Pharmacy 360
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 30, 2023
Details:
Quillivant ER (methylphenidate) Oral Suspension and Chewable Tablet R is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Quillivant ER
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
Lead Product(s): Cebranopadol
Therapeutic Area: Psychiatry/Psychology Product Name: TRN-228
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $16.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 28, 2023
Details:
Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.
Lead Product(s): Cebranopadol
Therapeutic Area: Neurology Product Name: TRN-228
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Tris intends to leverage TRN-261's established safety profile and continue further development of TRN-261 within target pain indications. TRN-261 shows potential to deliver strong efficacy and safety, while providing patients an alternative to traditional opioids.
Lead Product(s): TRN-261
Therapeutic Area: Neurology Product Name: TRN-261
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2022
Details:
Dyanavel XR oral suspension (amphetamine) is a CNS stimulant that affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control used for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years and older.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Dyanavel XR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pediatrix Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 01, 2022
Details:
QuilliChew ER (methylphenidate hydrochloride) is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: QuilliChew
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
In a human clinical study, Tris established about 100% bioavailability for one dose of its formulation against two doses of XYREM at 4.5 gm each, equivalent to the 9.0 gm maximum dose of sodium oxybate.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
DYANAVEL XR is a central nervous system stimulant prescription medicine used for the treatment of ADHD in people 6 years and older. DYANAVEL XR (amphetamine) may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Dyanavel XR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
